<DOC>
	<DOCNO>NCT00389636</DOCNO>
	<brief_summary>Patients randomize receive TheraGauze alone Regranex treat diabetic foot ulcer condition . The purpose study provide sponsor pilot information regard ability TheraGauze promote wound heal examine synergy Regranex treatment diabetic foot ulcer .</brief_summary>
	<brief_title>TheraGauze™ Alone Regranex®Gel 0.01 % Plus TheraGauze™ Treatment Wagner Stage I Diabetic Foot Ulcers</brief_title>
	<detailed_description>This study evaluate use TheraGauzeT ( Soluble Systems , LLC ) wind dress , polymer hydrogel chemically impregnated rayon/polyester form fabric , form pliable , conform solid matrix . TheraGauze FDA Class I exempt ( regulation # 21CFR , product code 5878.4022 ) . It hypothesize material useful treatment full-thickness diabetic ulcer . It hypothesize material enhance action Regranex ( becaplermin ) gel provide optimal environment growth factor function . This study observe patient outcome follow diabetic foot ulcer treatment TheraGauze without use Regranex .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Patients 18 year old old ; diagnose insulindependent noninsulindependent diabetes mellitus ( 5.5 % &lt; HgBA1C &lt; 12 % ) ; foot ulcer extend epidermis dermis expose tendon bone ; diagnosis chronic diabetic ulcer ; viable wound bed granulation tissue determine bleed follow debridement ; ulcer size least 1 cm2 great 16cm2 ; sign informed consent form . wound present least 4 week time screen . Patients ulcer less 1cm2 great 16cm2 size ; severe arterial disease ( ankle brachial index ( ABI ) less 0.65 ) ; history radiation therapy ulcer site ; use corticosteroid &gt; 10mg prednisone daily use immune suppressive , severely immunocompromised patient ; ulcer nondiabetic pathophysiology ; vasculitis , severe rheumatoid arthritis , collagen vascular disease ; malnutrition ( define albumin &lt; 2.5 g/dL ) ; know allergy hypersensitivity component either TheraGauze Regranex ; erythema purulence associate severe infection wound site ; sign symptom cellulitis , osteomyelitis , necrotic avascular ulcer bed ; undergo hemodialysis ; uncontrolled diabetes ( define HgB A1c &gt; 12 % ) deficient blood supply ulcer ( define capillary fill time &gt; 3 second tip toe ) Charcot 's neuroarthropathy determine clinical and/or radiographic examination ; sickle cell disease ; expose bone , tendon , fascia ; currently enrol clinical evaluation another investigational device drug , receive investigational treatment diabetic foot ulcer last 30 day ; unable comply procedure describe protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Foot</keyword>
	<keyword>Extremity</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Wound</keyword>
	<keyword>Gauze</keyword>
</DOC>